Romidepsin
- Generic Name
- Romidepsin
- Brand Names
- Istodax
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36N4O6S2
- CAS Number
- 128517-07-7
- Unique Ingredient Identifier
- CX3T89XQBK
- Background
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
- Indication
用于在已接受至少1次既往全身治疗的患者中皮肤T-细胞淋巴瘤的治疗(CTCL)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
- Associated Therapies
- -
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Ryan Wilcox
- Target Recruit Count
- 11
- Registration Number
- NCT03547700
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT03534180
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
- Conditions
- Metastatic Breast CarcinomaRecurrent Breast CarcinomaRecurrent Hodgkin LymphomaRefractory Hodgkin LymphomaBreast AdenocarcinomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Nodal Marginal Zone LymphomaRecurrent Mycosis FungoidesRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
- Interventions
- Drug: BelinostatDrug: CarfilzomibDrug: Copanlisib HydrochlorideBiological: DaratumumabDrug: Fludeoxyglucose F-18Drug: Gemcitabine HydrochlorideOther: Laboratory Biomarker AnalysisBiological: NivolumabBiological: ObinutuzumabBiological: PembrolizumabProcedure: Positron Emission TomographyBiological: RituximabDrug: RomidepsinOther: SalineBiological: Trastuzumab
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 39
- Registration Number
- NCT03432741
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
- Conditions
- Interventions
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Jennifer Amengual
- Registration Number
- NCT03355768
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
- Conditions
- Recurrent Anaplastic Large Cell LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Mycosis FungoidesRefractory Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Angioimmunoblastic T-Cell LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT03278782
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 148
- Registration Number
- NCT03161223
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 50
- Registration Number
- NCT03141203
- Locations
- 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
🇬🇧Derriford Hospital, Plymouth, United Kingdom
🇬🇧Southampton General Hospital, Southampton, United Kingdom
Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03041012
- Locations
- 🇬🇧
Guy's and St Thomas', London, United Kingdom
🇩🇰Department of Infectious Diseases, Odense, Denmark
🇩🇰Dept. of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
Romidepsin Plus 3BNC117 Phase 2a Study
- Conditions
- Interventions
- First Posted Date
- 2016-07-29
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 48
- Registration Number
- NCT02850016
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
🇩🇰Aarhus University Hospital, Aarhus, Denmark
🇩🇪University of Cologne, Cologne, Germany
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 114
- Registration Number
- NCT02783625
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸University of Washington School of Medicine in St. Louis, Saint Louis, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.